EBV+ lymphoproliferative disease following prolonged chemotherapy for refractory LCH

Pediatric Blood and Cancer

Volumn 50, Issue 3, 2008, Pages 728-730

  Lee, Dean A ^a,b   Tatevian, Nina ^a   Herring, Ruth A ^a   McClain, Kenneth L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Epstein barr virus; Langerhans cell histiocytosis; Lymphoproliferative disease

Indexed keywords

ASPARAGINASE; CLADRIBINE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ANAPHYLAXIS; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CELLULAR IMMUNODEFICIENCY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; HISTIOCYTOSIS X; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LANGERHANS CELL; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS REACTIVATION;

6-MERCAPTOPURINE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CYTARABINE; DOXORUBICIN; DRUG THERAPY, COMBINATION; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; FEMALE; HERPESVIRUS 4, HUMAN; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; LYMPHOMA, LARGE B-CELL, DIFFUSE; METHOTREXATE; MYCOSES; PREDNISONE; RECURRENCE; VINBLASTINE; VINCRISTINE; VIRUS ACTIVATION;

EID: 38549150278     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21121     Document Type: Article

References (21)

1. The French Langerhans' Cell Histiocytosis Study Group. A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child 1996;75:17-24.
2. Titgemeyer C, Grois N, Minkov M, et al. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol 2001;37:108-114.
3. McClain KL, Gonzalez JM, Jonkers R, et al. Need for a cooperative study: Pulmonary Langerhans cell histiocytosis and its management in adults. Med Pediatr Oncol 2002;39:35-39.
4. Gadner H, Heitger A, Grois N, et al. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol 1994;23:72-80.
5. McClain KL. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother 2005;6:2435-2441.
6. Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer 2004;42:438-444.
7. McClain K, Jin H, Gresik V, et al. Langerhans cell histiocytosis: Lack of a viral etiology. Am J Hematol 1994;47:16-20.
8. Rolland A, Guyon L, Gill M, et al. Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol 2005;174:3067-3071.
9. McClain KL, Cai YH, Hicks J, et al. Expression profiling using human tissues in combination with RNA amplification and microarray analysis: Assessment of Langerhans cell histiocytosis. Amino Acids 2005;28:279-290.
10. McClain KL. Immunodeficiency states and related malignancies. Cancer Treat Res 1997;92:39-61.
11. Feng WH, Cohen JI, Fischer S, et al. Reactivation of latent Epstein-Barr virus by methotrexate: A potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 2004;96:1691-1702.
12. Lenz G, Golf A, Rudiger T, et al. Epstein-Barr virus-associated B-cell non-Hodgkin lymphoma following treatment of hairy cell leukemia with cladribine. Blood 2003;102:3457-3458.
13. Stine KC, Saylors RL, Saccente S, et al. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2004;43:81-84.
14. Honda R, Ohno Y, Iwasaki T, et al. Langerhans' cell histiocytosis after living donor liver transplantation: Report of a case. Liver Transpl 2005;11:1435-1438.
15. Chen CJ, Ho TY, Lu JJ, et al. Identical twin brothers concordant for Langerhans' cell histiocytosis and discordant for Epstein-Barr virus-associated haemophagocytic syndrome. Eur J Pediatr 2004;163:536-539.
16. Shimakage M, Sasagawa T, Kimura M, et al. Expression of Epstein-Barr virus in Langerhans' cell histiocytosis. Hum Pathol 2004;35:862-868.
17. Purtilo DT, Cassel CK, Yang JP, et al. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1975;1:935-940.
18. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000;11:113-116.
19. Collins MH, Montone KT, Leahey AM, et al. Autopsy pathology of pediatric posttransplant lymphoproliferative disorder. Pediatrics 2001;107:E89.
20. Rooney CM, Loftin SK, Holladay MS, et al. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995;89:98-103.
21. Rogers BB, Browning I, Rosenblatt H, et al. A familial lymphoproliferative disorder presenting with primary pulmonary manifestations. Am Rev Respir Dis 1992;145:203-208.